Transaction DateRecipientSharesTypePriceValue
1st September 2020Inc. Innoviva,4,672,897Open or private purchase$2.68$12,499,999.48
11th June 2020Inc. Innoviva,12,677,490Open or private purchase$2.50$31,693,725.00
27th March 2020Inc. Innoviva,7,717,661Open or private purchase$2.87$22,149,687.07
4th February 2020Life Sciences Viii, L.P. Frazier6,360,272Conversion of derivative$0.00
4th February 2020Life Sciences Viii, L.P. Frazier2,099,019Conversion of derivative$0.00
4th February 2020Life Sciences Viii, L.P. Frazier1,074,467Conversion of derivative$0.00
4th February 2020Life Sciences Viii, L.P. Frazier500,000Open or private purchase$17.00$8,500,000.00
9th January 2020Life Sciences Viii, L.P. Frazier50,000Open or private sale$5.00$250,010.00
18th January 2019Life Sciences Viii, L.P. Frazier372,439Open or private purchase$5.37$1,999,997.43
Entasis Therapeutics Holdings
Entasis Therapeutics Holdings logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections.


Ticker: ETTX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1724344
Employees: 33
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $51 M (0%)
Other Assets, Current: $1 M (-49%)
Assets, Current: $55 M (11%)
Property, Plant and Equipment, Net: $267 Th (-22%)
Other Assets, Noncurrent: $63 Th (0%)
Assets: $56 M (10%)
Accounts Payable, Current: $2 M (22%)
Liabilities, Current: $6 M (-18%)
Liabilities: $7 M (-19%)
Common Stock, Value, Issued: $27 Th (107%)
Common Stock, Shares, Issued: $27 M (105%)
Additional Paid in Capital, Common Stock: $212 M (20%)
Retained Earnings (Accumulated Deficit): $163 M (21%)
Stockholders' Equity (Parent): $49 M (0%)
Liabilities and Equity: $56 M (10%)
Research and Development: $10 M (-53%)
General and Administrative Expenses: $3 M (-53%)
Operating Income/Loss: $13 M (-53%)
Provision for income taxes: $73 Th (-49%)